Marie Viprey

Dr. Marie Viprey

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2019 in PLOS ONE
Verified
Journal Article
Open access
BCBenjamin Castagné
Benjamin Castagné
MVMarie Viprey
Marie Viprey
JMJulie Martin
Julie Martin
ASAnne-Marie Schott
Anne-Marie Schott
MCMichel Cucherat
Michel Cucherat
MSMartin Soubrier
Martin Soubrier
Our objective was to compare the cardiovascular safety of tocilizumab and other biological disease-modifying antirheumatic drugs (bDMARD) in rheumatoid arthritis using a network meta-analysis (NMA). A systematic literature search through May 2018 identified randomized controlled trials (RCT) or observational studies (cohort only) reporting cardiovascular outcomes of tocilizumab (TCZ) and/or abatacept (ABA) and/or rituximab (RTX) and/or tumor necrosis factor inhibitors (TNFi) in rheumatoid arthritis patients. The composite primary outcome was the rate of major adverse cardiovascular outcomes (MACE, myocardial infarction (MI), peripheral artery disease (PAD) and cardiac heart failure (CHF)). 19 studies were included in the NMA, including 11 RCTs and 8 cohort studies. We found less events with RTX (5.41 [1.70;17.26]. We found no difference between TCZ and other treatments. Concerning MI, we found no difference between TCZ and csDMARD (4.23 [0.22;80.64]), no difference between TCZ and TNFi (2.00 [0.18;21.84]). There was no difference between TCZ and csDMARD (1.51[0.02;103.50] and between TCZ and TNFi (1.00 [0.06;15.85]) for stroke event. With cohorts and RCT NMA, we found no difference between TCZ and other treatments for MACE (0.66 [0.42;1.03] with ABA, 1.04 [0.60;1.81] with RTX, 0.78[0.53;1.16] and 0.91 [0.54;1.51] with csDMARD), but the risk of myocardial infarction was lower with TCZ compared to ABA (0.67 [0.47;0.97]). We lacked data to compare TCZ and other bDMARD for stoke and MI. Not enough data was available to perform a NMA for CHF and PAD. Despite an increase in cholesterol levels, TCZ has safe cardiovascular outcomes compared to other bDMARD.

24 October 2019 in Disability and Rehabilitation
Verified
Journal Article
Closed access
CVClaire Della Vecchia
Claire Della Vecchia
MVMarie Viprey
Marie Viprey
JHJulie Haesebaert
Julie Haesebaert
ATAnne Termoz
Anne Termoz
CGCaroline GIROUDON
Caroline GIROUDON
ASAnne-Marie Schott
Anne-Marie Schott
Purpose: From a patient’s perspective, participation is a major determinant of quality of life. We aimed to review contextual factors, both personal and environmental, potentially associated with post-stroke participation. Methods: PubMed, PsycINFO, and Web of Science were searched for original quantitative and qualitative studies that investigated contextual factors of post-stroke participation, measured participation as the primary outcome, and met inclusion criteria. Results: Socio-demographic determinants were mostly unrelated with participation or showed discordant and inconclusive results. Although less investigated, psychosocial/psychological factors, particularly self-esteem and acceptance, were associated with participation in most studies. Motivation was found in qualitative studies, but discordant in quantitative ones. Environmental factors were even less investigated and mainly in qualitative studies among patients with communication disabilities. Among these, social support and attitude of others appeared to be major determinants of participation as well as physical environment and societal environment (services and polices). Conclusions: Personal factors, particularly psychological and psychosocial factors, were identified as positively associated with post-stroke participation. Environmental factors such as support, relationships, and positive attitudes towards patients were major facilitators of participation as well as physical environment and accessibility to appropriate services. Most of these factors are modifiable and should be addressed to improve patient participation.

30 November 2022 in Annals of Physical and Rehabilitation Medicine
Verified
Journal Article
Closed access
CVClaire Della Vecchia
Claire Della Vecchia
MPMarie Préau
Marie Préau
JHJulie Haesebaert
Julie Haesebaert
MVMarie Viprey
Marie Viprey
GRGilles Rode
Gilles Rode
ASAnne-Marie Schott
Anne-Marie Schott

23 October 2019 in PLOS ONE
Verified
Journal Article
Open access
PDF file
CVClaire Della Vecchia
Claire Della Vecchia
MPMarie Préau
Marie Préau
CCCamille Carpentier
Camille Carpentier
MVMarie Viprey
Marie Viprey
JHJulie Haesebaert
Julie Haesebaert
ASAnne-Marie Schott
Anne-Marie Schott
As acute stroke services improve, more persons experience mild stroke and need to cope daily with hidden disabilities, which may be influenced by how they perceive stroke, cognitively and emotionally. To investigate cognitive illness beliefs and emotional responses in persons with mild stroke and their possible influences on daily coping. Semi-structured interviews were conducted with 24 persons with mild stroke, on average 7.5 months (±0.89) after stroke occurrence. A thematic analysis on verbatim transcripts was guided by the Common-Sense Model of Self-Regulation. All participants experienced difficulties constructing an illness identity at both acute and chronic phase. Behavioral risk factors were less accepted as causes of stroke. Lack (or inappropriate timing) of information from healthcare providers led to limited medication knowledge and low perceived control of stroke recurrence which generated anxiety, fear, and low involvement in coping. Participants who considered stroke a chronic condition experienced more difficulties. Perceived support from relatives and healthcare providers was beneficial for participation in recovery and health behaviour change. Despite having mildly disabilities, participants reported difficulties developing illness beliefs conducive to coping, and dealing with their emotional responses. These elements should be considered in tailored programs to improve coping with hidden disabilities post-stroke.

12 October 2020 in European Journal of Neurology
Verified
Journal Article
Closed access
PDF file
MBMarine Barral
Marine Barral
HRHugo Rabier
Hugo Rabier
ATAnne Termoz
Anne Termoz
HSHassan Serrier
Hassan Serrier
CCCyrille Colin
Cyrille Colin
TGThe Stroke69 Study Group
The Stroke69 Study Group

1 September 2019 in Patient Preference and Adherence
Verified
Journal Article
Open access
PDF file
HRHéloïse Rouzé
Héloïse Rouzé
MVMarie Viprey
Marie Viprey
SASamuel Allemann
Samuel Allemann
Alexandra L DimaAlexandra L Dima
Alexandra L Dima
PCPascal Caillet
Pascal Caillet
STSandrine Touzet
Sandrine Touzet
Background: Cystic fibrosis (CF) is a life-shortening genetic condition that usually affects several organs and involves significant treatment burden. Adherence to medication is important for successful CF management. Objective: To describe medication adherence according to age, therapeutic class, and pharmaceutical form in adults and children followed in four regional CF centers in France. Methods: We conducted a cross-sectional study with non-transplanted patients followed in two adult and two pediatric centers during 2015 who were covered by the French National Health Insurance (NHI). Sociodemographic, clinical, hospitalization, and prescription data were collected from patient medical records. Medication dispensations were extracted from the regional French NHI database. Adherence was calculated over 12 months using continuous medication availability (CMA) accounting for dose adjustments and hospitalizations. Drug-specific CMA was computed in R with the AdhereR package for each medication prescribed more than 3 months, which was averaged to obtain a composite CMA score (cCMA) for all treatments and per therapeutic class as well as pharmaceutical form for each patient. Results: A total of 228 patients were included. The number of chronic medications increased with age (r=0.50, p<0.001): a median of 7 medications per patient were prescribed. The mean±SD cCMA was significantly different between age groups (p=0.0098): it was 0.71±0.20 for the 0–5 years age group, 0.73±0.16 for 6–11 years, 0.64±0.17 for 12–17 years, 0.57±0.23 for 18–25 years, and 0.65±0.20 for the over 25 years age group. cCMA varied significantly according to pharmaceutical forms: the mean±SD cCMA was 0.70±0.21 for oral medications and 0.54±0.28 for inhaled medications (p<0.001). Conclusion: This study suggests that adherence to medication regimens in CF patients remains suboptimal and varies substantially between age groups and pharmaceutical forms. These variations in adherence should be considered when developing effective strategies to improve adherence.